Pulmonary Histoplasmosis in Three Austrian Travelers After a Journey to Mexico

Hoenigl, Martin; Schwetz, Ines; Wurm, Robert; Scheidl, Stefan; Olschewski, Horst; Krause, Robert

doi:10.1007/s15010-007-6298-2

Cited by 14 publications

(11 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Most cases (46.3%) were diagnosed in Spain, France, and Germany. There were six clusters of acute histoplasmosis involving 3-10 travellers to Latin America who had visited bat-infested caves [98][99][100]108,109] and the members of a multinational student expedition to a Ugandan rainforest in which a hollow bat-infested tree was the possible source of infection [115]. Most of the immunocompetent patients had pulmonary histoplasmosis (60/83, 73.2%), which was associated with rheumatological manifestations (arthralgia and/or erythema nodosum) in 23.3% of cases (Table 6).…”

Section: Immunocompetent Patientsmentioning

confidence: 99%

Histoplasmosis Diagnosed in Europe and Israel: A Case Report and Systematic Review of the Literature from 2005 to 2020

Antinori

Giacomelli

Corbellino

et al. 2021

JoF

View full text Add to dashboard Cite

Human histoplasmosis is a mycosis caused by two distinct varieties of a dimorphic fungus: Histoplasma capsulatum var. capsulatum and H. capsulatum var. duboisii. In Europe, it is usually imported by migrants and travellers, although there have been some autochthonous cases, especially in Italy; however, most European physicians are unfamiliar with its clinical and pathological picture, particularly among immunocompromised patients without HIV infection. This systematic review of all the cases of histoplasmosis reported in Europe and Israel between 2005 and 2020 identified 728 cases diagnosed in 17 European countries and Israel described in 133 articles. The vast majority were imported (mainly from Central and South America), but there were also seven autochthonous cases (six in Europe and one in Israel). The patients were prevalently males (60.4%), and their ages ranged from 2 to 86 years. The time between leaving an endemic region and the diagnosis of histoplasmosis varied from a few weeks to more than 40 years. Progressive disseminated histoplasmosis was the most frequent clinical picture among people living with HIV infection (89.5%) or a different immunocompromising condition (57.1%), but it was also recorded in 6.2% of immunocompetent patients. Twenty-eight cases were caused by Histoplasma duboisii. Immunocompromised patients without HIV infection had the worst outcomes, with a mortality rate of 32%.

show abstract

Section: Immunocompetent Patientsmentioning

confidence: 99%

Histoplasmosis Diagnosed in Europe and Israel: A Case Report and Systematic Review of the Literature from 2005 to 2020

Antinori

Giacomelli

Corbellino

et al. 2021

JoF

View full text Add to dashboard Cite

show abstract

“…Over the last two decades, the incidence of invasive fungal infections (IFIs) has increased worldwide 1–3 . Traditionally, Candida albicans was the most common cause of IFI but mould infections, in particular invasive aspergillosis (IA) and zygomycosis, as well as non‐albicans candidiasis and endemic community‐acquired mycoses in the Americas have dramatically increased in importance 4–6 . At particularly high risk for difficult‐to‐treat and often fatal IFIs are patients with prolonged neutropenia and patients undergoing allogeneic haematopoietic stem cell transplantation (HSCT) 7–10 .…”

Section: Introductionmentioning

confidence: 99%

“…[1][2][3] Traditionally, Candida albicans was the most common cause of IFI but mould infections, in particular invasive aspergillosis (IA) and zygomycosis, as well as nonalbicans candidiasis and endemic community-acquired mycoses in the Americas have dramatically increased in importance. [4][5][6] At particularly high risk for difficult-to-treat and often fatal IFIs are patients with prolonged neutropenia and patients undergoing allogeneic haematopoietic stem cell transplantation (HSCT). [7][8][9][10] In patients receiving HSCT, IFI occurred in 3.7% of patients (7.8% in allogeneic HSCT recipients vs. 1.2% in autologous HSCT recipients) with Aspergillus spp.…”

Section: Introductionmentioning

confidence: 99%

Epidemiology of invasive fungal infections and rationale for antifungal therapy in patients with haematological malignancies

Hoenigl

Zollner‐Schwetz

Sill

et al. 2011

Mycoses

Self Cite

View full text Add to dashboard Cite

Invasive fungal infections (IFIs) in patients with haematological malignancies are difficult to diagnose and outcome is often fatal. Over the 7-month study period, 117 cases with haematological malignancies receiving systemic antifungal treatment were included. Data regarding antifungal agents, dosage and reason for administration were recorded. Fungal infections in study patients were classified as possible, probable or proven according to recent European Organization for Research and Treatment of Cancer criteria. During the study period, 690 cases with haematological malignancies were admitted. A total of 117 cases received systemic antifungal therapy. Twenty-four of 117 patients (21%) had possible, six (5.1%) had probable and four (3.4%) had proven IFI. Seven of 10 probable and proven infections were caused by Candida spp., 2 by Aspergillus spp. and 1 by a fungus belonging to Zygomycetes. Fifty-two of 117 patients (44%) received antifungal prophylaxis, 81 of 117 (69%) received empirical (31/117; 26%) or pre-emptive (50/117; 43%) antifungal therapy and four of 117 patients (3.4%) directed antifungal therapy. Mostly, systemic antifungal therapy was administered empirically or pre-emptively. Twenty-nine per cent of cases receiving systemic antifungal treatment met the international consensus criteria of mostly possible IFI, whereas 71% did not. Proven invasive fungal infections were rare.

show abstract

“…Histoplasmosis and especially progressive disseminated histoplasmosis (PDH) in patients with immunodeficiency is caused by Histoplasma capsulatum , a fungus endemic in North and South America, Africa, Asia, and Australia [ 63 ]. Diagnosis is challenging; in particular, the current alternatives to culture diagnostics are too expensive for resource-challenged countries [ 64 ].…”

Section: Poc Diagnosis Of Cryptococcosismentioning

confidence: 99%

Point of Care Testing for the Diagnosis of Fungal Infections: Are We There Yet?

Prattes

Heldt

Eigl

et al. 2016

Curr Fungal Infect Rep

View full text Add to dashboard Cite

Diagnostic tools for invasive fungal infections have continuously improved within the last decades. Nowadays, cultural methods, antigen testing, and molecular tests, such as polymerase chain reaction, are widely used. These methods, however, are accompanied with different limitations as various availability, various turnaround time or high costs. A new generation of point-of-care test has shown promising results in various studies and may overcome some of these limitations. We therefore reviewed the literature for the most promising new point-of-care tests for invasive aspergillosis (Aspergillus-specific lateral-flow device test, Aspergillus proximity ligation antigen assay), cryptococcosis (cryptococcal lateral-flow assay), and for histoplasmosis (loop-mediated isothermal amplification assay).

show abstract

Pulmonary Histoplasmosis in Three Austrian Travelers After a Journey to Mexico

Cited by 14 publications

References 18 publications

Histoplasmosis Diagnosed in Europe and Israel: A Case Report and Systematic Review of the Literature from 2005 to 2020

Histoplasmosis Diagnosed in Europe and Israel: A Case Report and Systematic Review of the Literature from 2005 to 2020

Epidemiology of invasive fungal infections and rationale for antifungal therapy in patients with haematological malignancies

Point of Care Testing for the Diagnosis of Fungal Infections: Are We There Yet?

Contact Info

Product

Resources

About